Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9334473 | 1.00 | LMNA (0.37) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL17392918 | 0.98 | KDM4E (0.37) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL17392916 | 0.98 | KDM4E (0.37) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL8273057 | 0.84 | LMNA (0.36) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL27111119 | 0.81 | LMNA (0.34) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL697217 | 0.81 | KDM4E (0.35) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL30753324 | 0.81 | KDM4E (0.37) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL15831734 | 0.81 | KDM4E (0.35) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL9334509 | 0.81 | KDM4E (0.37) | LMNAALDH1A1KDM4ECYP2D6CYP2C9 | |
| SCHEMBL2905487 | 0.79 | BACE1 (0.46) | ALDH1A1KDM4ECYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014105958-A2 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, FGFR3, FGFR1 | LMNA 4080/4885ALDH1A1 3567/4885KDM4E 3165/4885 |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, IPMK, IP6K2 | LMNA 4413/4885ALDH1A1 3068/4885KDM4E 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.